key: cord-0927865-ssazpwm9
authors: Quaresima, Micol; Quaresima, Virginia; Naldini, Matteo Maria; Cirillo, Daniela Maria; Ferrari, Angela; Mazzi, Angela; Tesini, Ester Maria Carla; Leone, Maria Cristina; Merli, Francesco
title: Clinical management of a Nigerian patient affected by sickle cell disease with rare blood group and persistent SARS‐CoV‐2 positivity
date: 2020-07-04
journal: EJHaem
DOI: 10.1002/jha2.53
sha: 0917412d2edbf18ed1433d3487613c0772d1a79f
doc_id: 927865
cord_uid: ssazpwm9

nan

Considering that by March 2020, the Italian health system was struggling with the implementation of a harmonized national public health strategy for the containment of the COVID-19 outbreak, testing for SARS-CoV-2 was not performed, and, given her mildly symptomatic status, the patient was discharged with Azithromycin 500 mg/day for 6 days and paracetamol for fever and pain relief. The patient was instructed about distancing measures from the rest of her family and home-quarantine.

The patient was previously known at the ASMN Hematology department for her homozygous SCD status with a blood group (BG) B Rh positive, and a rare phenotype characterized by: ccDee (Rh System); kk (Kell System); Fya-b-(Duffy system); Jka+b-(Kidd system);

M+N-S-s-(MNS system); Cw-(Cw system); Le a-b-(Lewis system);

Lu a-b+ (Lutheran system); Kp a-b-(Kp system In the absence of cough, fever, and respiratory distress (SoPO 2 = 98%), ACS was likely excluded also in consideration that radiographic evidence of pulmonary infiltrates was already evident much earlier (>48 h) than the onset of chest pain. HbS dosing was not performed because it is not among the routine emergency examinations. The patient was discharged with the advice to continue home self-isolation and clinical follow up was maintained through frequent phone calls. During the first phase of COVID-19 outbreak, mildly symptomatic patients were more preferably cared for at home, rather than admitted to overwhelmed hospitals. COVID-19 infection has been already reported in SCD patients worldwide. In France, a 45-years-old SCD patient suffering from COVID-19 has been successfully treated with Tocilizumab (TCZ), an anti-human IL-6 receptor monoclonal antibody [7] . Moreover, other SCD cases affected by SARS-CoV-2 in the United States [8, 9] Although there is limited data on the interactions between COVID-19 and SCD, previous data from the H1N1 outbreak highlighted [8] increased risk of SCD-related events such as ACS upon viral infection but whether SCD might influence the clinical manifestation of COVID-19 is unknown. One may speculate that the chronic pulmonary hypoperfusion, as a consequence of the reiteration of VOCs in SCD patients, may slow down the COVID-19 associated immune infiltrate recruitment and cytokine release. Therefore, we wonder if in addition to protecting factors such as sex and young age, the SCD background could have contributed to milder COVID-19 manifestations. More data across different age categories in this particular population are needed to investigate whether the SCD background is linked to different manifestations of COVID-19.

Lastly, a clear analysis will be needed to understand whether national health programs in Italy and elsewhere during the COVID-19

pandemic properly responded to the needs of immigrants and patients suffering from chronic diseases.

The authors declare that they have no conflict of interest.

Virginia Quaresima https://orcid.org/0000-0001-8858-3236

Relevance of RH variants in transfusion of sickle cell patients

Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients

Pain-measurement tools in sickle cell disease: where are we now?

The changing profile of sickle cell disease in Italy

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Life-Threatening Infectious Complications in Sickle Cell Disease: A Concise Narrative Review

Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab

COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient

COVID-19 infection in patients with sickle cell disease

Vasoocclusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19)

Clinical management of a Nigerian patient affected by sickle cell disease with rare blood group and persistent SARS-CoV-2 positivity